PI
BLUE

Pennant Investors’s bluebird bio BLUE Stock Holding History

Pennant Investors’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,370
Closed -$86K – 23
2024
Q2 		$86K Hold
4,370
– – 0.02% 45
2024
Q1 		$112K Hold
4,370
– – 0.03% 44
2023
Q4 		$121K Buy
+4,370
New +$266K 0.03% 42

Other funds holding BLUE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Pennant Investors's BLUE Position: Q3 2024 in Review

Pennant Investors sold out of bluebird bio (BLUE) in Q3 2024, closing a stake of 4,370 shares — an estimated $86K sold.

Pennant Investors first reported a position in BLUE in Q4 2023 and held it in 3 quarters. The position peaked at $121K in Q4 2023. 140 funds tracked by Wall St. Rank hold BLUE as of Q3 2024.

  • Pennant Investors reported no remaining bluebird bio position as of Q3 2024 after selling out during the quarter.
  • Pennant Investors sold 4,370 bluebird bio shares in Q3 2024, an estimated $86K.
  • Pennant Investors first reported a position in bluebird bio in Q4 2023 and held it in 3 quarters.
  • Pennant Investors's bluebird bio position peaked at $121K in Q4 2023.
  • 140 funds tracked by Wall St. Rank held bluebird bio as of Q3 2024.

Based on Pennant Investors's 13F filing for Q3 2024, filed 14 Nov 2024.